At the request of mutual customers Bristol-Myers Squibb and Abbott, Iconix Pharmaceuticals and Rosetta BioSoftware will develop a tool that will enable Iconix's DrugMatrix data to operate on Rosetta's Resolver system, the tool vendors said last week.

As a result, researchers at the pharma giants -both of whom co-partner with Iconix- and new Rosetta and Iconix customers will now be able to convert Iconix's reference database of genomic analyses of chemical compounds into data that can be managed and analyzed on the Rosetta system.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.